DEF: Palisade Bio Proposes Reverse Split to Meet Nasdaq Listing Rules

Palisade Bio, Inc. will hold its 2025 Annual Meeting to vote on director elections, auditor ratification, and a reverse stock split to regain Nasdaq compliance.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on October 17, 2025, at 10:00 a.m. Pacific Time.
• Stockholders will vote on three proposals: the election of three directors, the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2025, and the approval of a reverse stock split.
• The proposed reverse stock split would amend the company's Certificate of Incorporation to effect a split ratio of not less than 1-for-5 and not greater than 1-for-50, at the Board's discretion, to be completed on or before December 31, 2025.
• The primary purpose of the reverse stock split is to regain compliance with The Nasdaq Capital Market's $1.00 per share minimum bid price requirement, following a notice received on April 30, 2025.
• The company reported a net loss of $14,438,000 for the fiscal year ended December 31, 2024, compared to a net loss of $12,300,047 in 2023 and $14,260,000 in 2022.
• As of September 12, 2025, there were 9,119,152 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the necessity of a reverse stock split to maintain Nasdaq listing, persistent net losses, and recent director resignations. While proactive steps are being taken, the underlying issues indicate significant challenges.

Positives

• The Board is proactively addressing Nasdaq listing compliance through the proposed reverse stock split, aiming to maintain market access.
• A formal equity compensation program for non-employee directors was approved in June 2024, designed to incentivize and retain talent.
• Executive base salaries were increased for 2025, with J.D. Finley's salary rising to $575,000 and Mitchell Jones's to $440,000.
• The Board removed its classified structure on February 29, 2024, transitioning to annual elections for most directors, which enhances corporate governance.

Negatives

• The company received a notice from Nasdaq on April 30, 2025, for non-compliance with the $1.00 minimum bid price requirement, indicating a low stock price.
• Persistent net losses were reported: $14,438,000 in 2024, $12,300,047 in 2023, and $14,260,000 in 2022.
• The necessity of a reverse stock split suggests underlying challenges in maintaining shareholder value and market perception.
• Several directors resigned in early 2024, including James R. Neal, Stephanie C. Diaz, Dr. Cristina Csimma, Dr. Robert Trenschel, and Dr. Mary Ann Gray.
• Delinquent Section 16(a) reports for three former directors were filed late in February 2024.

Risks

• There is no assurance that the reverse stock split, if effected, will increase the market price of common stock in proportion to the reduction in shares or result in a permanent price increase.
• Even if the reverse stock split is approved and implemented, there is no guarantee that the company will continue to meet the Nasdaq Capital Market's continued listing requirements.
• The reverse stock split may result in some stockholders owning 'odd lots' (less than 100 shares), which can be more difficult or costly to sell.
• The reduced number of shares outstanding after the reverse stock split could adversely affect trading liquidity.
• The increase in authorized but unissued shares relative to outstanding shares, resulting from the reverse stock split, could be construed as having an anti-takeover effect.

Future Outlook

The company intends to monitor its common stock's closing bid price and may implement a reverse stock split, if approved by stockholders, on or before December 31, 2025, to regain compliance with Nasdaq's minimum bid price requirement. The Board aims for a higher stock price to attract long-term investors, reduce volatility, and improve employee retention.

Management Comments

• Our Board of Directors Unanimously Recommends that Stockholders Vote FOR the Election of the Nominees to the Board of Directors.
• Our Board of Directors Recommends a Vote FOR the Ratification of the Appointment of Baker Tilly US, LLP as our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025.
• Our Board of Directors Unanimously Recommends a Vote FOR the Approval of the Reverse Stock Split.

Industry Context

The biotechnology industry often sees companies, particularly those in early or clinical stages, facing challenges in maintaining stock prices above exchange minimums. Reverse stock splits are a common strategy employed by such companies to meet listing requirements and potentially attract broader investor interest, though their long-term effectiveness varies.

Comparison to Industry Standards

• The need for a reverse stock split to maintain Nasdaq listing is a common occurrence for small-cap biotechnology companies, particularly those without significant revenue or late-stage clinical assets.
• The persistent net losses of approximately $12-14 million annually are typical for development-stage biotech firms heavily investing in R&D, but without specific industry benchmarks or competitor data in the filing, a direct comparison of financial performance is not feasible.
• The executive compensation structure, including base salary, performance-based bonuses, and long-term equity incentives, aligns with general industry practices for attracting and retaining talent in the competitive biotech sector, with the 2024 cash compensation for named executive officers approximating the 25th percentile of the peer group.

Management Changes

Corporate Governance

Related Party Transactions

• On August 16, 2022, J.D. Finley, the company's Chief Executive Officer and Chief Financial Officer, invested $25,000 in an underwritten offering, acquiring 133 units consisting of common stock and warrants.
• In April 2023, Armistice Capital LLC, a then holder of greater than 5% of the company's outstanding common stock, purchased shares and warrants for an aggregate of $2,999,930.11 in a registered offering and concurrent private placement.
• In December 2024, Armistice Capital LLC, a then holder of greater than 5% of the company's outstanding common stock, purchased Class A and Class B Units for an aggregate of $4,999,687.13 in a registered offering.

Stakeholder Impact

• **Shareholders:** Will vote on key proposals, including a reverse stock split that could impact share price, liquidity, and ownership structure (due to fractional shares). Face the risk of delisting if Nasdaq compliance is not met.
• **Employees:** Retention and motivation are linked to stock price and equity compensation, which the proposed reverse split aims to improve.
• **Collaborators/Vendors:** Delisting from Nasdaq could result in a loss of confidence, potentially harming business relationships and future prospects.
• **Creditors:** The company's persistent net losses and capital raising activities are relevant to creditors assessing financial stability and risk.

Next Steps

• Stockholders will vote on the proposed director elections, auditor ratification, and reverse stock split at the Annual Meeting on October 17, 2025.
• The Board of Directors will decide, at its discretion, whether to effect the reverse stock split and at what ratio (between 1-for-5 and 1-for-50) on or before December 31, 2025, if approved by stockholders.
• Final voting results will be published in a Current Report on Form 8-K within four business days after the Annual Meeting.

Key Dates

Recommendation

The company is taking necessary steps, such as proposing a reverse stock split, to address its Nasdaq listing compliance issue, which is a positive for maintaining market access. However, the persistent net losses and the inherent risks associated with reverse stock splits (e.g., no guaranteed long-term price increase, potential for reduced liquidity) suggest that significant challenges remain. While management is proactive, the fundamental financial health and market perception require careful monitoring, warranting a 'hold' rather than a 'buy' or 'sell' at this juncture.

Keywords

Palisade Bio, PALI, Nasdaq, Reverse Stock Split, Proxy Statement, Corporate Governance, Biotechnology, SEC Filing, Director Election, Auditor Ratification, Executive Compensation, Financial Performance